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High density Huh7.5 cell hollow 
fiber bioreactor culture for high-
yield production of hepatitis C virus 
and studies of antivirals
Anne F. Pihl1, Anna F. Offersgaard1, Christian K. Mathiesen1, Jannick Prentoe1, Ulrik Fahnøe  1, 
Henrik Krarup  2, Jens Bukh1 & Judith M. Gottwein  1
Chronic hepatitis C virus (HCV) infection poses a serious global public health burden. Despite the recent 
development of effective treatments there is a large unmet need for a prophylactic vaccine. Further, 
antiviral resistance might compromise treatment efficiency in the future. HCV cell culture systems are 
typically based on Huh7 and derived hepatoma cell lines cultured in monolayers. However, efficient 
high cell density culture systems for high-yield HCV production and studies of antivirals are lacking. 
We established a system based on Huh7.5 cells cultured in a hollow fiber bioreactor in the presence 
or absence of bovine serum. Using an adapted chimeric genotype 5a virus, we achieved peak HCV 
infectivity and RNA titers of 7.6 log10 FFU/mL and 10.4 log10 IU/mL, respectively. Bioreactor derived 
HCV showed high genetic stability, as well as buoyant density, sensitivity to neutralizing antibodies 
AR3A and AR4A, and dependency on HCV co-receptors CD81 and SR-BI comparable to that of HCV 
produced in monolayer cell cultures. Using the bioreactor platform, treatment with the NS5A inhibitor 
daclatasvir resulted in HCV escape mediated by the NS5A resistance substitution Y93H. In conclusion, 
we established an efficient high cell density HCV culture system with implications for studies of 
antivirals and vaccine development.
Hepatitis C virus (HCV) is an enveloped, positive-stranded RNA virus of the Flaviviridae family1. The single 
open reading frame (ORF) encodes a polyprotein of ~3000 amino acids (aa) that is cleaved into 10 proteins: Core, 
envelope glycoproteins E1 and E2, the viroporin p7, and the nonstructural (NS) proteins NS2, NS3, NS4A, NS4B, 
NS5A and NS5B2–4.
Each year 2 million new infections with HCV are estimated to occur worldwide. Approximately 80% of these 
individuals are not able to clear the infection and therefore develop chronic hepatitis5,6. Worldwide, 70–150 mil-
lion individuals are estimated to be chronically infected7–9. Individuals with HCV-induced hepatitis typically 
show no or unspecific symptoms, but have an increased risk of developing liver cirrhosis and hepatocellular 
carcinoma. Thus, HCV is the leading cause of liver transplantations and is estimated to cause at least 400.000 
deaths annually8.
Treatment with recently developed direct-acting antivirals (DAA) typically results in high cure rates9–11. 
However, only a fraction of infected individuals is treated, mostly because few infected individuals are aware of their 
status due to the lack of symptoms prior to the development of end-stage liver disease; further, because of the high 
cost of DAA9. In addition, evidence suggests that DAA treatment does not prevent reinfection and that for some 
patients treatment does not eliminate the risk of developing hepatocellular carcinoma following HCV eradication12. 
Finally, future efficacy of even the most efficient DAA regimens, including recently introduced pangenotypic 
regimens, will likely be compromised by the emergence and spread of resistant HCV variants8,10,11,13, as has been 
observed for other pathogens for which antimicrobials have been developed. Therefore, there is a large unmet 
need for a prophylactic HCV vaccine13,14.
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To study HCV resistance to DAA and to develop a cell culture based HCV vaccine, cell culture systems are 
required15. All efficient infectious HCV cell culture systems employ the human hepatoma cell line Huh7 or 
derived cell lines, such as the Huh7.5 cell line, which are typically cultured in monolayers in cell culture flasks16. 
Initially, only a single HCV genotype 2a isolate (JFH1) could recapitulate the complete viral life cycle in cell cul-
ture17,18. Subsequently, various infectious cell culture systems producing HCV particles of the major genotypes 
were developed15. Of these systems, a JFH1-based recombinant with genotype 5a specific Core-NS2 with cell 
culture adaptive mutations showed the highest efficacy19. However, the described culture systems have several 
limitations. Cells grown in three-dimensional cultures might better resemble the in vivo environment20,21. Thus, 
for certain studies, such as studies of antivirals, a more physiological arrangement of cells than provided in mon-
olayer cultures is considered beneficial20–22. In addition, virus yields in monolayer culture are typically limited, 
while development of a whole virus HCV vaccine and other applications, such as morphological studies of HCV 
particles, require large amounts of viral particles. However, no high-yield, high cell density HCV cell culture 
systems for efficient production of HCV have been established. Here we aim to establish a hollow fiber bioreac-
tor platform for high cell density growth of the Huh7.5 cell line and the efficient production of HCV particles. 
Furthermore, we demonstrate the use of this platform for studies of DAA.
Results
Huh7.5 cell cultivation and HCV production in a hollow fiber bioreactor (HFBR). To estab-
lish high density cell culture with the Huh7.5 cell line, typically cultured in monolayer in cell culture flasks, 
we explored cultivation in a HFBR. Following cell seeding in serum-containing medium (DMEM + 10%FBS), 
glucose consumption gradually increased and reached ~1 g/day on day 7 post cell seeding (Fig. 1). From day 7, 
cultivation was continued in serum-free medium (AEM), as recommended for production of biological products 
in cell culture23. Glucose consumption decreased after media exchange to ~0.5 g/day on day 8 post cell seeding, 
but reached ~1 g/day on day 11 (Fig. 1).
HCV production in HFBR was initially established under serum-containing conditions. In a second exper-
iment, glucose consumption reached ~0.2 g/day on day 4 post cell seeding, when the cells were infected with 
1.25 × 106 FFU of HCV (Fig. 2a). Every second day approximately 20 mL supernatant were harvested from the 
HFBR extracapillary space. HCV infectivity titers of harvested supernatants increased soon after infection and 
peaked at 7.0 log10 FFU/mL on day 9 post cell seeding (day 5 post infection). Titers remained high for an extended 
period of time, but decreased to <6.0 log10 FFU/mL on day 31 following cell seeding and to <5.0 log10 FFU/mL 
on day 69, when the culture was terminated (Fig. 2b). The cumulative virus yield reached 1.09 × 109 FFU at day 
25 post cell seeding (day 21 post infection). Additional harvests only contributed slightly to the total amount of 
1.31 × 109 FFU, achieved when the experiment was terminated (Fig. 2c). The total amount of HCV Core accu-
mulated during the main production phase (day 5–25 post cell seeding) was 0.76 × 108 amol, amounting to ~1.6 
μg Core (Fig. 2c). HCV RNA titers peaked at 9.1 log10 IU/mL on day 17 post cell seeding and declined to 7.4 log10 
IU/mL at the end of cultivation (Fig. 2d). The mean specific infectivity of HFBR produced HCV was 1/133 FFU/
IU (see Supplementary Fig. S1).
To establish HCV production under serum-free conditions we carried out an experiment in which 
serum-containing DMEM was changed to serum-free AEM on day 14 post cell seeding (day 9 post infection) 
(Fig. 3a). A peak HCV infectivity titer of 7.6 log10 FFU/mL was recorded on day 26 post cell seeding; subse-
quently titers gradually decreased to 5.8 log10 FFU/mL on day 40, when the culture was terminated (Fig. 3b). 
A total amount of 2.7 × 109 FFU were produced until day 40 post cell seeding (Fig. 3c). The largest quantity of 
2.4 × 109 FFU were produced in AEM, while 3.2 × 108 FFU were produced in DMEM. The total amount of HCV 
Core accumulated during the main production phase in AEM (day 16–32 post cell seeding) was 1.0 × 108 amol, 
amounting to ~2.1 μg Core (Fig. 3c). HCV RNA titers peaked at 10.4 log10 IU/mL on day 10 post cell seeding. The 
HCV RNA titers declined to 8.3 log10 IU/mL on day 40 at the end of the cultivation (Fig. 3d). The mean specific 
infectivity of HFBR produced HCV was 1/111 FFU/IU (see Supplementary Fig. S1).
Long-term culture in HFBR did not result in further cell culture adaptation of HCV. To eval-
uate if prolonged culture in HFBR resulted in further cell culture adaptation of HCV, we first compared viral 
spread characteristics and infectivity titers of HCV derived either from HFBR (HCVHFBR) or standard cell cul-
ture (HCVcc). HCVHFBR and HCVcc showed similar spread kinetics with viral spread to most culture cells on day 
6 post infection (Fig. 4a), following infection of standard Huh7.5 cell cultures at MOI 0.003 with virus stocks 
specified in the Fig. 4 legend. Furthermore, HCVHFBR and HCVcc showed similar infectivity titers throughout the 
Figure 1. Cultivation of Huh7.5 cells in a hollow fiber bioreactor. 108 Huh7.5 cells were seeded in a hollow 
fiber bioreactor in DMEM + 10% FBS. At day 7 post cell seeding, when glucose consumption was 1055 mg/day, 
DMEM was replaced with serum-free medium (AEM).
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Figure 2. Production of HCV in a HFBR in DMEM + 10% FBS. (a) 108 Huh7.5 cells were seeded in a HFBR 
and cultured in DMEM +10% FBS. On day 4 post cell seeding, when glucose consumption was 220 mg/
day, cells were infected with 1.25 × 106 FFU of HCV second passage stock. Arrow indicates time of infection; 
hexagons indicate high-glucose harvest. (b) Infectivity titers were determined as FFU/mL for each harvest 
collected following infection; shown are means of three replicates with error bars indicating standard error of 
the mean (SEM). (c) The total amount of FFU/HCV Core was determined by the addition of amounts of FFU/
HCV Core from individual harvests. (d) HCV RNA titers were determined as IU/mL for selected harvests.
Figure 3. Production of HCV in a HFBR in serum-free AEM. (a) 1.8 × 108 Huh7.5 cells were seeded in a 
hollow fiber bioreactor in DMEM + 10% FBS and infected with 1.25 × 106 FFU of HCV second passage stock on 
day 5 post cell seeding (arrow), when glucose consumption was 290 mg/day. At day 14 post cell seeding DMEM 
was replaced with serum-free AEM. (b–d) Determination of HCV infectivity titers, accumulated FFU/HCV 
Core and RNA titers were carried out as described for Fig. 2.
www.nature.com/scientificreports/
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kinetic experiment (Fig. 4b). NGS analysis of the entire coding sequence revealed high genetic stability of HCV 
derived from early and late harvests from the bioreactors (Fig. 2 and 3) (see Supplementary Table S1). The ratio 
between coding and non-coding mutations (πN/πS), which ranged from 0.42 to 0.60, suggested negative selec-
tion. Further, pairwise distance analysis revealed a low level of heterogeneity of the viral population with only 
slight increases in heterogeneity over time (π < 10−3) (see Supplementary Table S1).
HCV particles from HFBR have similar density as standard cell culture derived HCV. As biophysical 
properties of HCV particles can depend on culture conditions24, we determined the buoyant densities of HCV 
derived from HFBR (Fig. 2 and 3) and from standard culture using equilibrium buoyant density ultracentrifuga-
tion on iodixanol gradients. In line with previous findings24, regardless of the cultivation method, viruses cultured 
in serum-containing medium showed a heterogeneous density profile (Fig. 5a and c), while viruses cultured in 
serum-free medium showed a homogeneous density profile (Fig. 5b and d). For sf-HCVcc 81% of viruses were 
found in fractions with densities of 1.10–1.12 g/mL (Fig. 5b) and for sf-HCVHFBR 96% of the viruses were found 
in these fractions (Fig. 5d). In contrast, these fractions contained only 23% of viruses for HCVcc (Fig. 5a) and 25% 
of viruses for HCVHFBR (Fig. 5c). In general, HCV RNA peaked with infectivity, suggesting an association with 
infectious HCV particles (Fig. 5a–d).
HFBR derived HCV show similar sensitivity to neutralization with human monoclonal IgG 
and blocking of co-receptors CD81 and SR-BI as HCV from standard cell culture. To investigate 
whether the cultivation in the bioreactors had an influence on viral characteristics mediated by the HCV enve-
lope proteins, we carried out neutralization and receptor blocking assays. We first determined HCV sensitivity 
to well-defined human monoclonal antibodies AR3A (Fig. 6a) that targets a conformational epitope in E2 and 
AR4A (Fig. 6b) that targets a conformational epitope in E1E225,26. HCVcc, sf-HCVcc, HCVHFBR and sf-HCVHFBR 
showed similar sensitivity to both monoclonal antibodies with IC50 values ranging from 0.01 to 0.03 μg/mL. We 
also tested if the requirement for entry co-receptors CD81 (Fig. 6c) and SR-BI (Fig. 6d) to establish infection 
was altered in HCV derived from the bioreactors. HCVcc, sf-HCVcc, HCVHFBR and sf-HCVHFBR showed simi-
lar dependency on co-receptor CD81 as antibody-mediated blocking of co-receptor CD81 resulted in 88–95% 
blocking of infection. HCV grown on different platforms and under different conditions also showed similar 
dependency on co-receptor SR-BI with antibody-mediated blocking of co-receptor SR-BI resulting in 40–51% 
blocking of infection.
HCV culture in HFBR as model system for studies of antiviral resistance. Cell densities in tissues 
are better mimicked by HFBR than monolayer cell cultures, making HFBR relevant platforms for studies of anti-
virals27,28. We previously studied HCV escape from antivirals in standard cell culture29–33, and in this study we 
set out to investigate if the HFBR could be used as a platform to study HCV escape from the DAA daclatasvir 
targeting HCV NS5A34. In a HFBR, cells were infected with 1.25 × 106 FFU of HCV at day 5 post cell seeding 
when glucose consumption was ~0.6 g/day (Fig. 7a and b). On day 9 post cell seeding (day 4 post infection) 
serum-containing medium was exchanged for serum-free AEM. HCV infectivity and HCV RNA titers of the 
harvests increased after infection and peaked at 6.9 log10 FFU/mL and 8.6 log10 IU/mL on day 11 post cell seeding 
(Fig. 7c and d). On day 27 post cell seeding daclatasvir was added to the medium at a concentration correspond-
ing to 64xEC50 of HCV recombinants with NS5A of isolate JFH129 and on day 45 post cell seeding the daclatasvir 
concentration was increased to 1024xEC50 (Fig. 7a and b). Following initiation of daclatasvir treatment it was 
Figure 4. HFBR derived HCV show similar spread kinetics as standard monolayer cell culture derived HCV. 
Supernatant from harvest 6 and 33 of HFBR in DMEM + 10%FBS (HCVHFBRH6, HCVHFBRH33) (Fig. 2) and 
supernatant from harvest 11 and 18 of HFBR in serum-free AEM (sf-HCVHFBRH11, sf-HCVHFBRH18) (Fig. 3) 
were used to infect 106 Huh7.5 cells plated the previous day in T25 cell culture flasks at an MOI of 0.003 in 
parallel with standard cell culture derived HCV third passage stock (HCVcc). Viral spread in the cultures 
was monitored by (a) determination of the % of HCV antigen positive cells based on immunostaining (b) 
determination of supernatant HCV infectivity titers. HCV infectivity titers are means of three replicates with 
standard error of the mean (SEM); the lower cutoff indicated by the y-axis break, was up to 2.5 log10 FFU/mL.
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no longer possible to determine HCV infectivity titers (Fig. 7c). To investigate if infectious viruses were present 
in the bioreactor under treatment, we used harvest supernatants to infect cells in standard cell cultures desig-
nated derived cultures. All derived cultures became infected and showed peak titers of ~6 log10 FFU/mL. Direct 
sequence analysis of daclatasvir-treated HFBR derived HCV revealed presence of NS5A inhibitor resistance 
associated substitution Y93H in approximately 50% of the viral population at harvest 22 and 26, whereas most 
genomes were estimated to carry this substitution at harvest 31 (Fig. 7a and Supplementary Table S2). To confirm 
that Y93H in HFBR derived HCV conferred resistance to daclatasvir, we carried out a short-term treatment 
assay (see Supplementary Fig. S2). For HCV derived from the HFBR prior to treatment EC50 of daclatasvir was 
0.11 nM, while for HCV derived from the HFBR during treatment EC50 of daclatasvir was 291 nM. Thus, HFBR 
derived HCV escape variants showed 2645-fold resistance, in accordance with fold resistance values previously 
observed for JFH1 with Y93H29,35.
Given that HCV NS5A inhibitors interfere with HCV RNA replication2 and given that we previously had 
observed a decrease in HCV RNA titers during treatment with the NS5A inhibitor velpatasvir and the NS5B 
inhibitor sofosbuvir in standard monolayer cell cultures30,31, it was an unexpected finding that HCV RNA titers 
did not decrease during daclatasvir treatment in the bioreactor (Fig. 7d). To ensure the efficacy of daclatasvir 
treatment and to facilitate determination of HCV infectivity titers during treatment, we carried out iodixanol 
gradient ultracentrifugation of selected bioreactor harvests obtained prior to and following initiation of treat-
ment. We confirmed that daclatasvir treatment resulted in a strong decrease in the total amount of infectious 
HCV detected across all ultracentrifugation fractions: 2.4 × 105 FFU were detected in harvest 9 prior to treat-
ment, but only 2.1 × 103 FFU in harvest 12 on day 2 following initiation of treatment. In harvest 16 on day 10 
following initiation of treatment, no infectious viruses were detected in any of the analyzed fractions (Fig. 7e). 
While total amounts of HCV RNA measured by TaqMan real time PCR detected across all ultracentrifugation 
fractions were similar before and after initiation of treatment (Fig. 7e), we observed a >100-fold decrease in 
full-length HCV RNA following treatment initiation (Fig. 7f). Finally, we confirmed that in standard monolayer 
cell culture daclatasvir treatment resulted in a decrease in HCV RNA titers, which was similar to that observed 
Figure 5. HFBR and standard monolayer cell culture derived HCV show similar density profiles. HCV 
particles used for density profiling on 10–40% iodixanol gradients were derived from: (a) standard cell culture 
in DMEM + 10%FBS using a third passage stock (HCVcc); (b) standard cell culture in serum-free AEM (sf-
HCVcc); (c) harvest 6 of HFBR cultivation in DMEM + 10%FBS (HCVHFBRH6) (Fig. 2); or (d) harvest 11 of 
HFBR cultivation in serum-free AEM (sf-HCVHFBRH11) (Fig. 3). Following ultracentrifugation 18 fractions 
were collected, density, HCV infectivity and HCV RNA titers of each fraction were determined. Relative 
recovery of infectious virus and HCV RNA per fraction was calculated by relating the amounts detected in each 
fraction to the total amounts collected in all fractions.
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under sofosbuvir treatment (see Supplementary Fig. S3). Thus, in the bioreactors daclatasvir treatment resulted 
in a decrease in infectious viruses and full-length viral RNA. However, in contrast to standard cell culture, in the 
bioreactor treatment did not have a significant impact on HCV RNA titers determined by TaqMan PCR using 
short amplicons.
Discussion
We provide proof-of-concept for high cell density culture of the highly HCV permissive Huh7.5 hepatoma cell 
line in a hollow fiber bioreactor. We showed that this platform can be used to produce high titer HCV stocks, with 
bioreactor derived HCV showing similar characteristics as HCV derived from standard monolayer cell culture. 
In addition, we demonstrated the use of this platform for studies of HCV antivirals.
High density mammalian cell culture is required for various applications including production of pharmaceu-
tical proteins, monoclonal antibodies, and vaccine antigens36–38. Most licensed antiviral vaccines employ whole 
viral particles as antigens39,40. For several of these vaccines, including polio, rabies, and Japanese encephalitis virus 
vaccines, production platforms have been optimized using classical cell lines such as Vero cells, which are typi-
cally grown in stirred tank bioreactors on microcarrier beads20,41. However, production of certain other viruses is 
not supported by established cell lines and culture conditions. For example, cell lines required for production of 
certain viruses grow adherent to surfaces and might be easier to culture in bioreactors inducing less shear stress 
than stirred tank bioreactors37,38.
Efficient production of HCV in cell culture is limited to adherent Huh7 derived cell lines, such as Huh7.5 
cells15,16. Establishment of high density cultures of these cells to enable high-yield production of HCV is of great 
importance for the development of a whole HCV particle vaccine42–44, but also for other applications, such as 
studies of HCV morphology, and studies that require infection at high MOI. To our knowledge there are only 
two reports on high density Huh7 cell culture for production of HCV in bioreactors. Murakami et al. describe 
cultivation of Huh7 cells expressing a full-length genotype 1b HCV recombinant on carrier beads in a radial-flow 
bioreactor, which only resulted in limited production of HCV particles45. Sainz et al. cultivated Huh7 cells on 
Figure 6. HFBR and standard monolayer cell culture derived HCV show similar sensitivity to monoclonal 
HCV neutralizing antibodies and similar dependency on entry co-receptors CD81 and SR-BI. Neutralization 
assays with human monoclonal antibodies (a) AR3A and (b) AR4A and receptor blocking assay with (c) 
anti-CD81 and (d) anti-SR-BI were carried out as described in Materials and Methods. HCV was from (i) a 
third passage stock generated in standard cell culture in DMEM + 10%FBS (HCVcc); (ii) a forth passage stock 
generated in standard cell culture in serum-free AEM (sf-HCVcc); (iii) HFBR cultivation in DMEM + 10%FBS 
(HCVHFBRH6) (Fig. 2); or (iv) HFBR cultivation in serum-free AEM (sf-HCVHFBRH11) (Fig. 3). (a and b) The 
% neutralization was calculated and curves were fitted as described in Materials and Methods. Data points are 
means of three replicates with SEM. IC50 values are shown (μg/mL). (c and d) The % blocking was calculated as 
described in Materials and Methods. Data points are means of eight replicates with SEM.
www.nature.com/scientificreports/
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Figure 7. Induction of HCV escape from a direct acting antiviral in HFBR. (a) Timeline of Huh7.5 cell 
cultivation in DMEM + 10%FBS and serum-free AEM, indicating infection with HCV and initiation of 
treatment with different concentrations of the NS5A inhibitor daclatasvir (DCV). HCV from HFBR harvests 
(1000 μL, 50 μL or 5 μL) were used for infection of 106 Huh7.5 cells plated the previous day in T25 cell culture 
flasks (derived cultures). Peak infectivity titers in derived cultures are reported. Amino acid at NS5A position 
93 according to the H77 reference sequence (GenBank accession no AF009606) was determined by Sanger 
sequencing for selected harvests and derived cultures. *, H at position 93 was present in ~50% of viral genomes. 
(b) 8 × 107 Huh7.5 cells were seeded in a hollow fiber bioreactor in DMEM + 10% FBS and infected with 
1.25 × 106 FFU of HCV third passage stock on day 5 post cell seeding, when glucose consumption was 590 mg/
day (arrow). At day 9 post cell seeding DMEM was replaced with serum-free AEM. Treatment with daclatasvir 
at 7.8 nM (corresponding to 64 x EC5029) was initiated at day 27 post cell seeding; at day 45 the concentration 
was increased to 124.2 nM (corresponding to 1024 x EC50). On day 59 the treatment was terminated.  
www.nature.com/scientificreports/
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microcarrier beads using a rotating wall vessel bioreactor46. When infected with the HCV genotype 2a recombi-
nant JFH1, this platform yielded HCV infectivity titers of 4–5 log10 FFU/mL.
In the bioreactor used here, peak HCV infectivity titers of up to 7.6 log10 FFU/mL were achieved using a 
JFH1-based recombinant with genotype 5a specific Core-NS2. These titers were considerably higher than 
observed for the same virus in monolayer cell culture19, and higher than titers observed by Murakami et al. 
and Sainz et al.45,46, as well as titers observed for cell culture derived HCV in general. This is likely due to con-
centration of the virus by retention in the bioreactor cartridge, which is separated from the media supply. Also, 
media is supplied in perfusion mode, providing efficient exchange of nutrients, metabolites and oxygen47. We 
excluded that the high HCV infectivity titers observed were due to an increase in HCV fitness during high cell 
density culture, since monolayer cultures infected with bioreactor derived HCV did not yield increased infec-
tivity titers. In addition, next generation sequence analysis of HCV harvested from the bioreactor showed high 
genetic stability without indications of significant adaptation to high density culture conditions. In line with 
previous observations in monolayer cell cultures, we observed higher HCV infectivity titers in serum-free than 
in serum-containing high density cell culture24. During the main production phase in serum-free medium ~2 
μg HCV Core were produced in one bioreactor. Assuming a recovery of ~50% during downstream processing 
required for purification and concentration of HCV antigen, one bioreactor will eventually yield ~1 μg purified 
HCV Core antigen. This is in the range of what would be used in mouse immunogenicity studies for one immu-
nization of one animal. Of note, also human antiviral vaccines, such as the TBE vaccine, operate in this range. 
However, even though a larger model of the described bioreactor with a 4-fold greater surface area is available, 
high density Huh7.5 cell cultures in bioreactors allowing scalability to industrial scale are likely to be required for 
development of a whole HCV particle vaccine.
For development of a whole virus particle vaccine for human use, virus production under serum-free con-
ditions is required23. In contrast to the previous reports on Huh7 cell based production of HCV in bioreac-
tors45,46, we established high cell density production of HCV under serum-free conditions based on protocols 
previously developed in monolayer Huh7.5 cell culture24. As previously reported for HCV produced in monolayer 
serum-free cell culture, HCV produced in high cell density serum-free culture in the bioreactor also showed a 
homogeneous density profile. A homogeneous density profile is of great advantage for downstream purification 
processes relying on density-based separation, for example ultracentrifugation. In contrast to previous observa-
tions in a small-scale three-dimensional Huh7 cell culture model48, high density culture did not change the HCV 
density profile, suggesting that lipoprotein association was not altered compared to HCV derived from monolayer 
cell culture.
Further phenotypic characterization of bioreactor derived HCV showed that high cell density culture did 
not result in altered viral dependency on key HCV entry receptors, which is in line with previous findings48. In 
addition, HCV derived from high cell density and monolayer cell culture showed similar neutralization pro-
files indicating that important conformational neutralization epitopes on the envelope proteins showed similar 
accessibility to neutralizing antibodies, which is of importance for vaccine development. The specific infectiv-
ity of bioreactor produced HCV was slightly lower than that of HCV produced in monolayer cell culture (see 
Supplementary Fig. S1), which might be due to delayed clearance of non-full-length RNA from the bioreactor 
(also see discussion below).
In future studies, it would be of interest to use the developed platform to investigate the influence of HCV 
infection on the cellular metabolism such as glucose consumption.
Three-dimensional cell culture systems are used for various applications, and especially for studies of drug 
pharmaceuticals including antivirals. Thus, the hollow fiber bioreactor used in this study has previously been 
used for studies of antivirals22,49. While three-dimensional cell cultures have been developed for various cell types, 
liver cell systems are of special interest given the important role of the liver in drug metabolism and different 
three-dimensional liver cell models have been developed20,21,47,50–52. Various efforts have been undertaken to cul-
ture Huh7 cells in a three-dimensional arrangement52–57. However, only a limited number of studies investigated 
HCV infection in such cultures. Thus, in addition to the two bioreactor-based systems described above45,46, dif-
ferent small-scale systems have been developed45,48,58,59. Of these, only one system using Huh7.5 cells showed 
reasonable HCV production with infectivity titers of 4–5 log10 FFU/mL58. It should be noted that a smaller version 
of the bioreactor used here with a 7-fold smaller surface area is available, which could facilitate more extended 
analysis of antivirals and cell metabolism in future studies.
We obtained proof-of-concept that the established high density culture platform could be used to study HCV 
escape from DAA. Here, HCV escape occurred after a similar treatment interval as in a previous study in mon-
olayer cell cultures using the same NS5A inhibitor and an HCV recombinant with NS5A of the same isolate 
(JFH1)29. We previously found that not only viruses with the escape substitution Y93H, but also viruses with 
F28S were selected in daclatasvir treated monolayer cultures, whereas only viruses with Y93H were found in the 
bioreactor. Both substitutions confer high resistance to daclatasvir without obvious impairment of HCV fitness in 
(c and d) Determination of HCV infectivity titers and HCV RNA titers were carried out as described in Fig. 2. 
*, indicates HCV infectivity titers below assay detection level. (e) HCV from harvest 9, 12 and 16 were loaded 
on 10–40% iodixanol gradients. Following ultracentrifugation 18 fractions were collected as in Fig. 5. HCV 
infectivity and HCV RNA titers of each fraction were determined as described for Fig. 2. (f) RNA extracted 
from harvest 9, 12 and 14 at 1-, 10-, 100- and 1000-fold dilution was used for RT-PCR for generation of a full-
length amplicon spanning the complete HCV ORF. PCR products were visualized on a 1% agarose gel including 
a 1 kb DNA ladder; expected positions of full-length amplicons are indicated by arrows. Gel image was cropped 
as indicated by boxes; full-length gel is presented in Supplementary Fig. S4.
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vitro and are also found for HCV genotype 2 infected patients with treatment failure in vivo11,29. In the bioreactor, 
daclatasvir treatment resulted in a decrease in infectious viruses and full-length HCV RNA. However, in contrast 
to findings in monolayer cell culture30,31 (see Supplementary Fig. S3), treatment did not decrease HCV RNA 
titers determined by TaqMan real time PCR, which is based on a small amplicon. This might be due to relatively 
inefficient clearance of non-full-length HCV RNA from the bioreactor during harvests, caused by differences in 
handling compared to monolayer cell cultures: Thus, during harvests in monolayer cell culture, supernatant is 
removed completely, cells are washed with PBS and in serum-containing cultures also trypsinized before fresh 
medium is added. However, in the bioreactor supernatant is merely flushed out while replaced by fresh medium 
without cell washing and with a significant dead space. This hypothesis is further supported by the finding that 
Y93H was detected earlier in derived monolayer cultures infected with viable viruses showing resistance to 
daclatasvir than in the bioreactor, where apparently RNA fragments of non-viable viruses without resistance to 
daclatasvir persisted. Finally, also in non-treated bioreactors (Fig. 2 and 3) over time infectivity declined faster 
than HCV RNA levels determined by TaqMan real time PCR.
Importantly, Huh7.5 cells allow not only growth of HCV but also various other important and emerging 
human pathogenic viruses such as Zika, chikungunya, dengue, West Nile and yellow fever virus, for which vac-
cines or antivirals remain to be developed60–64.
In conclusion, we established high-yield production of HCV in high cell density human hepatoma cell culture, 
which might be an important step towards development of a whole HCV particle vaccine.
Materials and Methods
Standard monolayer cultivation of Huh7.5 cells. For expansion of cells for seeding in HFBR and for 
other experiments in standard cell culture, human hepatoma Huh7.5 cells16 were cultured at 37 °C and 5% CO2 in 
flasks in monolayers in Dulbecco’s Modified Medium (DMEM) with 10% fetal bovine serum (FBS) as described65. 
All culture media were supplemented with 100 U/mL penicillin +100 μg/mL streptomycin. Cells were split every 
2–3 days. HCV infection was carried out by inoculation with virus containing supernatant as specified followed 
by overnight incubation. Selected cultures were treated with daclatasvir or sofosbuvir (Acme Biosciences) as 
specified.
Standard monolayer cell culture derived HCV virus stocks. The HCV recombinant SA13/
JFH1Core-NS5B containing Core, E1, E2, p7 and NS2 of isolate SA13 (genotype 5a), and NS3, NS4A, NS4B, NS5A, 
NS5B and UTRs of isolate JFH1 (genotype 2a) was used and is referred to as HCV19. Throughout the study 
three virus stocks were used: (i) a previously described second passage virus stock grown in DMEM + 10%FBS 
(HCVcc)19; (ii) a derived third passage virus stock grown in DMEM + 10% FBS (HCVcc); (iii) a derived fourth 
passage virus stock grown in Adenovirus Expression Medium (AEM) without serum (LifeTechnologies) 
(sf-HCVcc) as described24. For all virus stocks, HCV genetic stability was confirmed by Sanger sequencing of the 
entire ORF. For each experiment the identity of the used stock is indicated in the figure legend.
Cultivation of Huh7.5 cells in HFBR. The HFBR cartridge C2011 (FiberCell Systems) was pre-cultured in 
phosphate buffered saline (PBS) for 48 hours, DMEM for 24 hours, and DMEM + 10%FBS for 24 hours by perfu-
sion of the intracapillary space. Huh7.5 cells cultivated under standard conditions were pelleted and resuspended 
in ~20 mL conditioned media collected prior to cell harvesting. Cells were seeded in the extracapillary space 
through the left side port. The HFBR was supplied with 125 mL DMEM + 10%FBS, administered into the intra-
capillary space, and maintained at 37 °C and 5% CO2. Glucose concentration of the media supply was measured 
daily using an AccuCheck device (Roche). Volume of the media supply was doubled when glucose concentration 
was <2 g/L until a maximal volume of 500 mL. Media flow in the HFBR was controlled by a peristaltic pump 
(FiberCell® Systems Duet Pump, # P3202), initially at ~80 mL/min and after 3–4 days at ~110 mL/min. HCV 
infection was carried out as specified by injecting HCV in a total volume of ~20 mL DMEM + 10%FBS into the 
extracapillary space. Serum-free culture was initiated by replacing the media in the extracapillary space with 
~20 mL and the media supply with 1 L serum-free AEM. High glucose harvest was carried out when glucose con-
sumption repeatedly was >1 g/day by flushing media and cells in the extracapillary space back and forth using 
both side ports, ultimately removing 20 mL cell suspension. For the treated HFBR, daclatasvir (Acme Bioscience) 
was diluted in dimethyl sulfoxide and added to the media supply at the specified concentrations.
Evaluation of HCV infected cultures. HCV spread in standard monolayer cell culture was evaluated 
by immunostaining using primary antibody anti-NS5A-9E10 at 1:300017, secondary antibody Alexa Flour® 488 
goat anti-mouse IgG at 1:500 (Lifetechologies) and Hoechst 33342 at 1:1000 as described24,65. The percentage of 
infected cells was determined by fluorescence with a Zeiss Axio Vert.A1 microscope.
To determine HCV infectivity titers, Huh7.5 cells were plated at 6000 cells/well in poly-D-lysine 96-well plates 
(Thermo Scientific). The next day, serially diluted viral supernatant was added (minimal dilution was 2-fold), 
testing each dilution in triplicates, and incubated for 48 hours24,66. Cells were immunostained as described using 
anti-NS5A-9E10 at 1:500017 and ECL sheep anti-mouse IgG horseradish-peroxidase linked whole antibody (GE 
Healthcare) at 1:500, followed by incubation with DAB substrate (DAKO). FFU were counted automatically with 
an ImmunoSpot Series 5 UV Analyzer (CTL Europe Gmbh) with customized software. Titers were calculated as 
described35,67.
HCV Core titers in culture supernatant were determined using the ARCHITECT HCV Ag assay (Abbott).
HCV RNA titers were determined from RNA extracted from 200 μL pre-diluted supernatant using the Total 
Nucleic Acid Isolation Kit (Roche Applied Science) and by Taqman real-time PCR as described65.
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Equilibrium density gradient ultracentrifugation. Ultracentrifugation was done as described68. In 
brief, OptiPrep™ Density Gradient Medium (Sigma) was used to make 10%, 20%, 30% and 40% iodixanol dilu-
tions in PBS. Dilutions were layered on top of each other using 2.5 mL per dilution in a Beckman centrifuge 
tube (Ramcon) and incubated at 4 °C. The following day, 1–2 mL of viral supernatant was loaded on top of the 
gradients, tubes were loaded in a Beckman SW-41 rotor and spun at 35,000 rpm for 18 hours at 4 °C in a Beckman 
XL-70 Ultracentrifuge. Following centrifugation, 18 fractions of ~550 μL were collected from the bottom of each 
vial and 400 μL of each fraction were weighed to determine the density68. The HCV infectivity titer of each frac-
tion was determined as described above.
Sequence analysis. For Sanger sequence analysis of NS5A Domain I, HCV RNA was extracted from 200 μL 
supernatant with High Pure Viral Nucleic Acid Kit (Roche). Superscript III reverse transcriptase (Thermo Fisher 
Scientific) was used for first-strand cDNA synthesis and Advantage 2 Polymerase Mix (Takara Bio) for PCR 
amplification as described65 (for specific primers and protocols see Supplementary Materials and Methods includ-
ing Supplementary Tables S3, S4, S5). Obtained amplicons were subjected to Sanger sequencing (Macrogen 
Europe).
Overall, sequence analysis of the complete ORF was done as described31. In brief, HCV RNA was extracted 
from 250 μL supernatant with TRIzol LS and chlorofrom in Gel Lock heavy Eppendorf tubes and puri-
fied on RNA Clean & Concentrator ™-5 columns (Zymo Research). Maxima H Minus Reverse Transcriptase 
(ThermoScientific) was used for first-strand cDNA synthesis and Q5® Hot start High-Fidelity DNA Polymerase 
(New England Biolabs) was used for PCR amplification (for specific primers and protocols see Supplementary 
Materials and Methods including Supplementary Tables S6, S7, S8)31. PCR samples were purified with DNA clean 
& concentrator ™-25 (Zymo Research) and used for Sanger sequencing or next generation sequence analysis 
(NGS). For NGS, the resulting PCR product was in addition purified by extraction from a 1% TAE gel using 
Zymoclean large fragment DNA recovery kit (Zymo Research). Library preparation was done by Macrogen Inc 
by Truseq Nano or in-house by NEBnext Ultra II DNA Library Prep Kit. Sequence analysis was carried out on 
the Illumina Miseq platform and DNA analysis was performed to determine single nucleotide polymorphism 
variants and genetic stability as described previously69,70.
HCV neutralization. Huh7.5 cells were plated at 6000 cells/well in poly-D-lysine 96-well plates. The next 
day, monoclonal antibodies AR3A or AR4A25,26 were serially diluted in DMEM + 10%FBS. Fifty µL of each dilu-
tion were mixed with an equal volume of virus in triplicates and incubated for 1 hour at 37 °C in parallel with 12 
replicates of virus only controls. Mixtures were added to the cells and incubated for 3 hours at 37 °C before wash-
ing with pre-warmed PBS. Fresh media were added followed by incubation for 48 hours at 37 °C. Cells were 
immunostained and single HCV positive cells were counted as described for HCV infectivity titrations35,71. The 
percent neutralization was calculated relating the number of single HCV-positive stained cells in wells infected 
with antibody-treated virus to the mean number of stained cells in wells with virus only controls. Antibody con-
centrations were logarithmically transformed, sigmoidal dose-response curves were f itted 
y top/(1 10 )log EC X hillslope( 10 50 )= + − ×  and IC50 values were calculated using Graphpad Prism 7.0.
HCV receptor blocking. Huh7.5 cells were plated at 6000 cells/well in poly-D-lysine 96-well plates. The 
next day eight replicate cultures were incubated with either 10 µg/mL of monoclonal antibody against CD81 (BD 
Pharmingen, JS81) or the control antibody 553447; or against SR-BI (C16-71) or the control antibody D72, diluted 
in DMEM + 10% FBS, while eight replicate cultures served as virus only controls. Following 1 hour incubation at 
37 °C, virus containing supernatants were added followed by incubation for 4 hours at 37 °C before washing with 
pre-warmed PBS. Fresh media were added followed by incubation for 48 hours at 37 °C. Cells were immunos-
tained and FFU were counted as described for infectivity titrations. The percent blocking was calculated relating 
the number of FFU in antibody-treated wells to the mean number of FFU in untreated wells. Data points are 
means of eight replicates with SEM.
Treatment assay. Huh7.5 cells were plated at 6000 cells/well in poly-D-lysine 96-well plates. The next day, 
virus containing supernatants were used for infection. The following day, daclatasvir was serially diluted in 
DMEM+10%FBS and added to the cells; each concentration was tested in triplicates. After 48 hours, cells were 
immunostained as described for HCV infectivity titrations and single HCV positive cells were counted as 
described for infectivity titrations. The percent inhibition was calculated relating the number of single 
HCV-positive stained cells in treated wells to the mean number of stained cells in untreated wells. Daclatasvir 
concentrations were logarithmically transformed, sigmoidal dose-response curves were fitted 
= + − ×y top/(1 10 )log EC X hillslope( 10 50 )  and IC50 values were calculated using Graphpad Prism 7.035,71.
Data Availability
HCV plasmids, protocols and data will be made available upon request.
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